A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Dv0002 913, New York

Dv0002 963, Rochester

Dv0002 941, Alpharetta

Dv0002 907, Miami

Dv0002 906, Boca Raton

Dv0002 936, Tampa

Dv0002 903, Ocala

Dv0002 962, Owensboro

Dv0002 917, Troy

Dv0002 900, West Des Moines

Dv0002 954, Skokie

Dv0002 915, St Louis

Dv0002 905, Overland Park

Dv0002 922, Baton Rouge

Dv0002 951, Houston

Dv0002 914, San Antonio

Dv0002 946, Phoenix

Dv0002 967, Santa Monica

Dv0002 955, San Diego

Dv0002 910, Bakersfield

Dv0002 943, San Luis Obispo

Dv0002 920, Portland

Dv0002 929, Portland

Dv0002 925, Brighton

Dv0002 901, Portsmouth

Dv0002 908, East Windsor

Dv0002 937, Johnston

Dv0002 672, Edmonton

Dv0002 673, Halifax

Dv0002 671, Hamilton

Dv0002 675, Markham

Dv0002 663, Mississauga

Dv0002 660, Montreal

Dv0002 665, Québec

Dv0002 651, Richmond Hill

Dv0002 653, Toronto

Dv0002 662, Toronto

Dv0002 657, Waterloo

Dv0002 670, Windsor